Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 Pathway Inactivation Drives SMARCB1 -deficient p53 -wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

13 Sept 2022

Abstract excerpt

Loss of the gene SMARCB1 drives the development of malignant rhabdoid tumors, epithelioid sarcomas, and other malignancies. The SMARCB1 protein is a core component of the SWI/SNF (SWItch/Sucrose Non-Fermentable) family of chromatin remodeling complexes, which are important regulators of gene expression and cell differentiation. Here, we use CRISPR-Cas9 to create germline smarcb1 loss of function in zebrafish. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36099437
DOI: 10.1158/1535-7163.mct-21-0770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 Pathway Inactivation Drives SMARCB1 -deficient p53 -wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionPMID 36099437Read ↗

SMARCB1 / INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJSemantic proximity Read ↗

tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafishSemantic proximity Read ↗

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsSemantic proximity Read ↗

Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future DevelopmentsSemantic proximity Read ↗

SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast CancerSemantic proximity Read ↗

Defining function of wild-type and patient specific <i>TP53</i> mutations in a zebrafish model of embryonal rhabdomyosarcomaSemantic proximity Read ↗

Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions.Semantic proximity Read ↗

Gene of the month: <i>SMARCB1</i>Semantic proximity Read ↗

SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodelingSemantic proximity Read ↗

Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expressionSemantic proximity Read ↗

SMARCB1 -deficient Tumors of Childhood: A Practical GuideSemantic proximity Read ↗

SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA SuppressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.